US1570851014 - Common Stock
CERUS CORP
NASDAQ:CERS (4/19/2024, 11:32:17 AM)
1.645
+0.01 (+0.3%)
Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 309 full-time employees. The company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as platelets, plasma, red blood cells. Its product or product candidate under development include INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, red blood cell and IFC transfusion products.
CERUS CORP
1220 Concord Ave Ste 600, 2550 Stanwell Drive
Concord CALIFORNIA 94520
P: 19252886000
CEO: William M. Greenman
Employees: 309
Website: https://www.cerus.com/
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cerus (NASDAQ:CERS) just reported results for the fourth quarter of 2023.Cerus ...
CERS stock results show that Cerus beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Here you can normally see the latest stock twits on CERS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: